Elizabeth A. Marchant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elizabeth A. Marchant has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Guilaine K. Boyce
Child and Family Research Institute, 4th Floor, Translational Research Building, 950 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4
1 shared publication - Manish Sadarangani
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada
1 shared publication - Pascal M. Lavoie
BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-10
Neonatal Sepsis due to Coagulase-Negative Staphylococci
Neonates, especially those born prematurely, are at high risk of morbidity and mortality from sepsis. Multiple factors, including prematurity, invasive life-saving medical interventions, and immaturity of the innate immune system, put these infants at greater risk of developing infection. Although advanced neonatal care enables us to save even the most preterm neonates, the very interventions sustaining those who are hospitalized concurrently expose them to serious infections due to common nosocomial pathogens, particularly coagulase-negative staphylococci bacteria (CoNS). Moreover, the health burden from infection in these infants remains unacceptably high despite continuing efforts. In this paper, we review the epidemiology, immunological risk factors, diagnosis, prevention, treatment, and outcomes of neonatal infection due to the predominant neonatal pathogen CoNS.
- 1 January 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-10
Open AccessNeonatal Sepsis due to Coagulase-Negative Staphylococci
Neonates, especially those born prematurely, are at high risk of morbidity and mortality from sepsis. Multiple factors, including prematurity, invasive life-saving medical interventions, and immaturity of the innate immune system, put these infants at greater risk of developing infection. Although advanced neonatal care enables us to save even the most preterm neonates, the very interventions sustaining those who are hospitalized concurrently expose them to serious infections due to common nosocomial pathogens, particularly coagulase-negative staphylococci bacteria (CoNS). Moreover, the health burden from infection in these infants remains unacceptably high despite continuing efforts. In this paper, we review the epidemiology, immunological risk factors, diagnosis, prevention, treatment, and outcomes of neonatal infection due to the predominant neonatal pathogen CoNS.